First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma

Author:

Chawla Sant P.1,Papai Zsuzsanna2,Mukhametshina Guzel3,Sankhala Kamalesh4,Vasylyev Leonid5,Fedenko Alexander6,Khamly Kenneth7,Ganjoo Kristen8,Nagarkar Rajnish9,Wieland Scott10,Levitt Daniel J.10

Affiliation:

1. Sarcoma Oncology Center, Santa Monica, California

2. State Health Center, Oncology Department, Budapest, Hungary

3. State Healthcare Institute Republican Clinical Oncological Center of the Ministry of Health of the Republic of Tatarstan, Kazan, Republic of Tatarstan, Russia

4. Cancer Therapy and Research Center, San Antonio, Texas5now with Sarcoma Oncology Center, Santa Monica, California

5. Institute of Medical Radiology, Kharkiv, Ukraine

6. Blokhin Cancer Research Center, Moscow, Russian Federation

7. Epworth Healthcare and Clinical Trials Research Centre, Richmond, Victoria, Australia

8. Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, California

9. Curie Manavata Cancer Centre, Nashik, Maharashtra, India

10. CytRx Corporation, Los Angeles, California

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3